Elizabeth R. Plimack, MD, MS, chief of the Division of Genitourinary Medical Oncology, director of Genitourinary Clinical Research, and professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, explains outcomes seen in the recent phase 3 KEYNOTE-426 clinical trial for previously untreated, advanced renal cell carcinoma (RCC). Patients were treated with a combination of pembrolizumab and axitinib, or sunitinib alone.
Dr. Plimack discusses the overall survival (OS) curves of favorable-, intermediate-, and poor-risk groups. OS curves of the favorable-risk groups have not yet diverged, though Dr. Plimack says this is not surprising since these groups tend to do well overall. However, in the intermediate- and poor-risk groups, OS is significantly increased in patients undergoing the combination drug treatment and correlates with depth of response (DOR).
Learn more by clicking here.